详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer.

92| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ ESCI

作者：

机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610042, Sichuan, China [2]Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application, Guangxi Medical University, Nanning 530021, Guangxi, China.

出处：

DOI：

关键词： Non-small cell lung cancer KRAS mutation immune checkpoints inhibitors tumor microenvironments cancer metabolism

摘要：

Non-small cell lung cancer (NSCLC) patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as surgical resection, radiotherapy, chemotherapies, and targeted medicines. However, the application of immune checkpoints inhibitors (ICIs) has dramatically altered the therapeutic pattern of NSCLC management. Clinical studies have indicated that some KRAS-mutant NSCLC patients could benefit from ICIs; however, the responses in some patients are still poor. This review intends to elucidate the mechanisms of resistance to immunotherapy in KRAS-driven NSCLC and highlight the TME functions altered by immunoinhibitors, immunostimulators, and cancer metabolism. These metabolic pathways could potentially be promising approaches to overcome immunotherapy resistance.© The Author(s) 2022.

基金：

语种：

被引次数：

WOS：

PubmedID：

JCR分区：

出版当年[2022]版：

无

最新[2023]版：

Q1 ONCOLOGY

影响因子： 4.6 最新[2023版] 4.4 最新五年平均 3.7 出版当年[2022版] 3.7 出版当年五年平均 0 出版前一年[2021版] 4.6 出版后一年[2023版]

第一作者：

第一作者机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610042, Sichuan, China

共同第一作者：

通讯作者：

通讯机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610042, Sichuan, China [*1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Renmin Road, Chengdu 610042, Sichuan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Alpha-solanine Anti-tumor Effects in Non-small Cell Lung Cancer Through Regulating the Energy Metabolism Pathway [2]Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer [3]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [4]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [5]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells [6]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [7]Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer [8]Expert consensus on perioperative treatment for non-small cell lung cancer [9]Neoadjuvant strategy for stage IIIA-N2 non-small cell lung cancer: chemoradiation or chemotherapy alone? [10]Radiation Dose Painting with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer